Literature DB >> 33712566

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis.

Kang Le1, Linda E Wellik2, Matthew J Maurer3, Ellen D McPhail4, Thomas E Witzig2, Mamta Gupta5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33712566      PMCID： PMC7955124          DOI： 10.1038/s41408-021-00447-x

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  12 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Authors:  Mamta Gupta; Matthew J Maurer; Linda E Wellik; Mark E Law; Jing Jing Han; Nazan Ozsan; Ivana N Micallef; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

3.  PVT1 dependence in cancer with MYC copy-number increase.

Authors:  Yuen-Yi Tseng; Branden S Moriarity; Wuming Gong; Ryutaro Akiyama; Ashutosh Tiwari; Hiroko Kawakami; Peter Ronning; Brian Reuland; Kacey Guenther; Thomas C Beadnell; Jaclyn Essig; George M Otto; M Gerard O'Sullivan; David A Largaespada; Kathryn L Schwertfeger; York Marahrens; Yasuhiko Kawakami; Anindya Bagchi
Journal:  Nature       Date:  2014-06-22       Impact factor: 49.962

4.  Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Authors:  Rebeca Manso; Margarita Sánchez-Beato; Julia González-Rincón; Sagrario Gómez; Federico Rojo; Manuela Mollejo; Mónica García-Cosio; Javier Menárguez; Miguel A Piris; Socorro M Rodríguez-Pinilla
Journal:  Br J Haematol       Date:  2017-10-26       Impact factor: 6.998

5.  Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

Authors:  Ghee Chong Koo; Soo Yong Tan; Tiffany Tang; Song Ling Poon; George E Allen; Leonard Tan; Soo Ching Chong; Whee Sze Ong; Kevin Tay; Miriam Tao; Richard Quek; Susan Loong; Kheng-Wei Yeoh; Swee Peng Yap; Kuo Ann Lee; Lay Cheng Lim; Daryl Tan; Christopher Goh; Ioana Cutcutache; Willie Yu; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Hong Lee Heng; Anna Gan; Choon Kiat Ong; Steve Rozen; Patrick Tan; Bin Tean Teh; Soon Thye Lim
Journal:  Cancer Discov       Date:  2012-06-15       Impact factor: 39.397

Review 6.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

7.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321

8.  Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

Authors:  Jing Jing Han; Megan O'byrne; Mary J Stenson; Matthew J Maurer; Linda E Wellik; Andrew L Feldman; Ellen D McPhail; Thomas E Witzig; Mamta Gupta
Journal:  Blood Cancer J       Date:  2018-11-12       Impact factor: 11.037

9.  c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.

Authors:  Kamini Singh; Jianan Lin; Yi Zhong; Antonija Burčul; Prathibha Mohan; Man Jiang; Liping Sun; Vladimir Yong-Gonzalez; Agnes Viale; Justin R Cross; Ronald C Hendrickson; Gunnar Rätsch; Zhengqing Ouyang; Hans-Guido Wendel
Journal:  J Exp Med       Date:  2019-05-29       Impact factor: 14.307

10.  Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.

Authors:  Weiping Li; Shiv K Gupta; Weiguo Han; Ryan A Kundson; Sara Nelson; Darlene Knutson; Patricia T Greipp; Sherine F Elsawa; Eduardo M Sotomayor; Mamta Gupta
Journal:  J Hematol Oncol       Date:  2019-07-09       Impact factor: 17.388
View more
  1 in total

1.  Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study.

Authors:  Yuan Yang; Zengwei Tang; Jiang Ji; Chen Yang; Miao Chen; Bing Han
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.